Table 3.
Association between SARS-CoV-2 variants, relevant mutations ((substitutions and deletions (Del)) in spike selected a priori and day-28 mortality by multivariable logistic regression analysis.
| All Patients | Day-28 Survivors | Day-28 Non-Survivors |
aOR a (95% CI) | p-Value | ||
|---|---|---|---|---|---|---|
| N = 411 | N = 293 | N = 118 | ||||
| Variants | Alpha | 195 (47.4%) | 144 (49.1%) | 51 (43.2%) | 1 (ref) | 0.347 |
| Pre-existing variant | 183 (44.5%) | 126 (43.0%) | 57 (48.3%) | 0.75 (0.45;1.25) | 0.263 | |
| Others | 33 (8.0%) | 23 (7.8%) | 10 (8.5%) | 1.31 (0.55;3.13) | 0.549 | |
| N501Y | 220 (53.5%) | 162 (55.3%) | 58 (49.2%) | 1.29 (0.80;2.11) | 0.299 | |
| N501Y x Alpha b | None | 191 (46.5%) | 131 (44.7%) | 60 (50.8%) | 1 (ref) | 0.565 |
| N501Y | 25 (6.1%) | 18 (6.1%) | 7 (5.9%) | 1.45 (0.53;3.97) | 0.473 | |
| N501Y and Alpha | 195 (47.4%) | 144 (49.1%) | 51 (43.2%) | 1.28 (0.77;2.11) | 0.342 | |
| Del 69–70 | 193 (47.0%) | 143 (48.8%) | 50 (42.4%) | 1.22 (0.75;1.98) | 0.426 | |
| Del 140–145 | 195 (47.4%) | 145 (49.5%) | 50 (42.4%) | 1.20 (0.74;1.95) | 0.468 | |
| Del 242–244 | 20 (4.9%) | 15 (5.1%) | 5 (4.2%) | 1.34 (0.44;4.09) | 0.607 | |
| L5F | 16 (3.9%) | 11 (3.8%) | 5 (4.2%) | 1.02 (0.32;3.27) | 0.978 | |
| L18F | 17 (4.1%) | 13 (4.4%) | 4 (3.4%) | 1.19 (0.34;4.10) | 0.788 | |
| D80A/G | 20 (4.9%) | 15 (5.1%) | 5 (4.2%) | 1.21 (0.40;3.66) | 0.733 | |
| S98F | 13 (3.2%) | 10 (3.4%) | 3 (2.5%) | 0.76 (0.18;3.17) | 0.703 | |
| K417N/T | 22 (5.4%) | 17 (5.8%) | 5 (4.2%) | 1.02 (0.34;3.02) | 0.976 | |
| L452R | 8 (1.9%) | 5 (1.7%) | 3 (2.5%) | 1.57 (0.33;7.41) | 0.569 | |
| S477N | 76 (18.5%) | 49 (16.7%) | 27 (22.9%) | 0.79 (0.43;1.45) | 0.447 | |
| E484K | 25 (6.1%) | 19 (6.5%) | 6 (5.1%) | 1.06 (0.38;2.94) | 0.908 | |
| A570D | 192 (46.7%) | 142 (48.5%) | 50 (42.4%) | 1.23 (0.76;2.00) | 0.406 | |
| D614G | 400 (97.3%) | 286 (97.6%) | 114 (96.6%) | 0.65 (0.16;2.68) | 0.550 | |
| H655Y | 6 (1.5%) | 4 (1.4%) | 2 (1.7%) | 1.07 (0.17;6.59) | 0.946 | |
| P681H | 190 (46.2%) | 140 (47.8%) | 50 (42.4%) | 1.29 (0.79;2.09) | 0.310 | |
| P681R | 9 (2.2%) | 5 (1.7%) | 4 (3.4%) | 2.72 (0.61;12.05) | 0.189 | |
a Multivariable analysis adjusted for age, SOFA score at admission, gender, and dexamethasone treatment; b This variable is from the interaction of the variable «alpha variant » and the variable « N501Y mutation»; aOR: adjusted odds ratio; 95% CI: 95% confidence interval.